Opportunity Radar

← Back to search

Grant

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
CA
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
PAR-24-293
Posted
Oct 1, 2024
Response due
Aug 18, 2027
Archive date
Sep 23, 2027
CFDA / Assistance listing
93.113,93.121,93.213,93.242,93.273,93.279,93.853,93.866,93.867
Contact
grantsinfo@nih.gov
Source
Grants.gov

Description

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

Similar open opportunities